Emerging Stocks Down Under 29 September 2020: Recce Pharmaceuticals, Energy One, 9Spokes

Emerging Stocks Down Under Edition #2

Recce Pharmaceuticals: Antibiotic resistance may have met its match

Today in Emerging Stocks Down Under it’s been a spectacular re-rating. The drug developer Recce Pharmaceuticals could be had for just 23 cents a share back on 24 March 2020.  It’s since gone up about sevenfold, thanks to a succession of favourable announcements related to Recce’s lead compound, a fast acting, broad-spectrum antibiotic called Recce 327.

Also in today’s edition, a look at energy trading and logistics software developer Energy One and application marketplace 9Spokes.

Get access to all editions through a 2-week FREE TRIAL. No charge on sign up.

Click here to read the previous edition of Emerging Stocks Down Under published 22 September 2020

For in-depth research reports or to keep up-to-date on the latest Stocks Down Under news see our parent company, Pitt Street Research, or follow us on Facebook and Twitter